<ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
<p>百时美施贵宝公司（NYSE:BMY - 免费报告）- Zacks Research 的股票研究人员在 12 月 16 日（星期二）发布的研究报告中上调了对百时美施贵宝 2026 年第二季度每股收益（EPS）的预期。Zacks Research 分析师团队现在预计这家生物制药公司将在该季度发布每股收益 1.67 美元，高于他们之前预测的 1.66 美元。市场普遍预计百时美施贵宝当前全年的每股收益为 6.74 美元。Zacks Research 还对百时美施贵宝 2026 财年的每股收益预期为 6.02 美元，2027 年第一季度的每股收益预期为 1.36 美元。</p>
<p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
<p>其他几位研究分析师最近也对 BMY 发表了评论。华尔街 Zen 在 11 月 8 日（星期六）的一份研究报告中将百时美施贵宝的评级从 “买入” 上调至 “强力买入”。摩根士丹利在 12 月 12 日（星期五）的一份研究报告中重申了 “减持” 评级，并将百时美施贵宝的目标价设定为 37.00 美元（上调自 36.00 美元）。Weiss Ratings 在 10 月 14 日（星期二）的一份研究报告中重新发布了对百时美施贵宝的 “持有（c-）” 评级。高盛集团在 12 月 2 日（星期二）的一份报告中重申了 “中性” 评级，并将百时美施贵宝的目标价设定为 57.00 美元（上调自 51.00 美元）。最后，BMO Capital Markets 在 11 月 17 日（星期一）的一份研究报告中重申了对百时美施贵宝的 “市场表现” 评级。五位投资分析师对该股票给予了买入评级，十四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司的当前共识评级为 “持有”，共识目标价为 54.62 美元。</p>
<ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
<p><strong>获取我们对 BMY 的最新股票分析</strong></p>
<h2>百时美施贵宝股价下跌 1.2%</h2>
<p>百时美施贵宝的股票在星期四开盘价为 53.56 美元。该股票的 50 天简单移动平均线为 47.35 美元，200 天简单移动平均线为 47.07 美元。该公司的市值为 1090.3 亿美元，市盈率为 18.09，PEG 比率为 8.30，贝塔值为 0.29。公司的债务与股本比率为 2.39，速动比率为 1.17，流动比率为 1.27。百时美施贵宝的 52 周低点为 42.52 美元，52 周高点为 63.33 美元。</p>
<ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
<p>百时美施贵宝（NYSE:BMY - 获取免费报告）在 10 月 30 日（星期四）最后发布了其财报。这家生物制药公司报告该季度每股收益为 1.63 美元，超出分析师的共识预期 1.52 美元 0.11 美元。该季度的营业收入为 122.2 亿美元，而共识预期为 117.5 亿美元。百时美施贵宝的净利润率为 12.57%，股本回报率为 76.53%。该公司的季度收入同比增长 2.8%。在去年同期，该公司每股收益为 1.80 美元。百时美施贵宝已将其 2025 财年的指导目标设定为 6.400-6.600 EPS。</p>
<h2>机构投资者对百时美施贵宝的看法</h2>
<p>大型投资者最近买入和卖出了该公司的股票。挪威银行在第二季度收购了百时美施贵宝的新头寸，价值约为 155.4154 亿美元。查尔斯·施瓦布投资管理公司在第二季度将其在百时美施贵宝的股份增加了 16.8%。查尔斯·施瓦布投资管理公司目前拥有 70,802,680 股该生物制药公司的股票，价值 32.77456 亿美元，此前在上个季度购买了额外的 10,195,775 股。Arrowstreet Capital Limited Partnership 在第二季度将其在百时美施贵宝的持股增加了 428.5%。Arrowstreet Capital Limited Partnership 目前拥有 11,311,281 股该生物制药公司的股票，价值 5.23599 亿美元，此前在上个季度购买了额外的 9,171,098 股。Man Group plc 在第二季度将其在百时美施贵宝的股份增加了 280.4%。Man Group plc 目前拥有 7,465,845 股该生物制药公司的股票，价值 3.45594 亿美元，此前在上个季度购买了额外的 5,503,391 股。最后，富兰克林资源公司在第二季度将其在百时美施贵宝的持股增加了 142.8%。富兰克林资源公司目前拥有 8,436,811 股该生物制药公司的股票，价值 3.90541 亿美元，此前在上个季度购买了额外的 4,961,869 股。76.41% 的股票目前由机构投资者和对冲基金持有。</p>
<h2>百时美施贵宝增加股息</h2>
<p>该公司最近还宣布了一项季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日（星期五）登记的股东将获得每股 0.63 美元的股息。这相当于每年 2.52 美元的股息，股息收益率为 4.7%。除息日期为 1 月 2 日（星期五）。这比百时美施贵宝之前的季度股息 0.62 美元有所增加。百时美施贵宝的股息支付比率目前为 83.78%。</p>
<h2>关于百时美施贵宝</h2>
<p>（获取免费报告）</p>
<p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括用于降低非瓣膜性房颤患者中风/全身栓塞风险以及治疗深静脉血栓症/肺栓塞的 Eliquis；用于多种抗癌适应症的 Opdivo，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；用于多发性骨髓瘤的 Pomalyst/Imnovid；用于活动性类风湿关节炎和银屑病关节炎的 Orencia；以及用于治疗费城染色体阳性慢性髓性白血病的 Sprycel。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>什么是国债？</li>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
<li>投资股票有不同类型</li>
<li>在上涨 35% 后，分析师关注铜巨头 Freeport 的更多上涨空间</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
<p>在你考虑百时美施贵宝之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而百时美施贵宝并不在名单上。</p>
<p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

百时美施贵宝

<p>Zacks Research 已将百时美施贵宝 2026 年第二季度每股收益（EPS）预估上调至 1.67 美元，之前为 1.66 美元。共识全年收益预估为每股 6.74 美元。多位分析师已发布评级，整体评级为 “持有”，目标价格为 54.62 美元。机构投资者已显著增加对该公司的持股</p>

<ul>
<li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li>
</ul>
<div class="lb-trans"><ul>
<li>为什么 GRAIL 股票可能成为生物科技的下一个重大突破</li>
</ul>
</div><p>Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Bristol Myers Squibb in a research report issued on Tuesday, December 16th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $1.67 for the quarter, up from their prior forecast of $1.66. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb's FY2026 earnings at $6.02 EPS and Q1 2027 earnings at $1.36 EPS.</p>
<div class="lb-trans"><p>百时美施贵宝公司（NYSE:BMY - 免费报告）- Zacks Research 的股票研究人员在 12 月 16 日（星期二）发布的研究报告中上调了对百时美施贵宝 2026 年第二季度每股收益（EPS）的预期。Zacks Research 分析师团队现在预计这家生物制药公司将在该季度发布每股收益 1.67 美元，高于他们之前预测的 1.66 美元。市场普遍预计百时美施贵宝当前全年的每股收益为 6.74 美元。Zacks Research 还对百时美施贵宝 2026 财年的每股收益预期为 6.02 美元，2027 年第一季度的每股收益预期为 1.36 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>百时美施贵宝</strong> 的提醒：</p>
</div><p>Several other research analysts also recently commented on BMY. Wall Street Zen upgraded Bristol Myers Squibb from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, November 8th. Morgan Stanley reaffirmed an &#34;underweight&#34; rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Weiss Ratings reissued a &#34;hold (c-)&#34; rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. The Goldman Sachs Group reaffirmed a &#34;neutral&#34; rating and set a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Finally, BMO Capital Markets reaffirmed a &#34;market perform&#34; rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Five investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of &#34;Hold&#34; and a consensus target price of $54.62.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对 BMY 发表了评论。华尔街 Zen 在 11 月 8 日（星期六）的一份研究报告中将百时美施贵宝的评级从 “买入” 上调至 “强力买入”。摩根士丹利在 12 月 12 日（星期五）的一份研究报告中重申了 “减持” 评级，并将百时美施贵宝的目标价设定为 37.00 美元（上调自 36.00 美元）。Weiss Ratings 在 10 月 14 日（星期二）的一份研究报告中重新发布了对百时美施贵宝的 “持有（c-）” 评级。高盛集团在 12 月 2 日（星期二）的一份报告中重申了 “中性” 评级，并将百时美施贵宝的目标价设定为 57.00 美元（上调自 51.00 美元）。最后，BMO Capital Markets 在 11 月 17 日（星期一）的一份研究报告中重申了对百时美施贵宝的 “市场表现” 评级。五位投资分析师对该股票给予了买入评级，十四位分析师给予了持有评级，一位分析师给予了卖出评级。根据 MarketBeat，该公司的当前共识评级为 “持有”，共识目标价为 54.62 美元。</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反弹所迷惑：市场风暴尚未结束</li>
</ul>
</div><p><strong>Get Our Latest Stock Analysis on BMY</strong></p>
<div class="lb-trans"><p><strong>获取我们对 BMY 的最新股票分析</strong></p>
</div><h2>Bristol Myers Squibb Trading Down 1.2%</h2>
<div class="lb-trans"><h2>百时美施贵宝股价下跌 1.2%</h2>
</div><p>Bristol Myers Squibb stock opened at $53.56 on Thursday. The stock has a 50-day simple moving average of $47.35 and a 200 day simple moving average of $47.07. The stock has a market capitalization of $109.03 billion, a P/E ratio of 18.09, a PEG ratio of 8.30 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $63.33.</p>
<div class="lb-trans"><p>百时美施贵宝的股票在星期四开盘价为 53.56 美元。该股票的 50 天简单移动平均线为 47.35 美元，200 天简单移动平均线为 47.07 美元。该公司的市值为 1090.3 亿美元，市盈率为 18.09，PEG 比率为 8.30，贝塔值为 0.29。公司的债务与股本比率为 2.39，速动比率为 1.17，流动比率为 1.27。百时美施贵宝的 52 周低点为 42.52 美元，52 周高点为 63.33 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周回顾 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, topping analysts' consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS.</p>
<div class="lb-trans"><p>百时美施贵宝（NYSE:BMY - 获取免费报告）在 10 月 30 日（星期四）最后发布了其财报。这家生物制药公司报告该季度每股收益为 1.63 美元，超出分析师的共识预期 1.52 美元 0.11 美元。该季度的营业收入为 122.2 亿美元，而共识预期为 117.5 亿美元。百时美施贵宝的净利润率为 12.57%，股本回报率为 76.53%。该公司的季度收入同比增长 2.8%。在去年同期，该公司每股收益为 1.80 美元。百时美施贵宝已将其 2025 财年的指导目标设定为 6.400-6.600 EPS。</p>
</div><h2>Institutional Investors Weigh In On Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>机构投资者对百时美施贵宝的看法</h2>
</div><p>Large investors have recently bought and sold shares of the company. Norges Bank acquired a new position in Bristol Myers Squibb during the second quarter valued at approximately $1,554,154,000. Charles Schwab Investment Management Inc. increased its stake in shares of Bristol Myers Squibb by 16.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company's stock valued at $3,277,456,000 after purchasing an additional 10,195,775 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in shares of Bristol Myers Squibb by 428.5% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company's stock worth $523,599,000 after buying an additional 9,171,098 shares in the last quarter. Man Group plc raised its stake in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock worth $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Bristol Myers Squibb by 142.8% in the second quarter. Franklin Resources Inc. now owns 8,436,811 shares of the biopharmaceutical company's stock worth $390,541,000 after acquiring an additional 4,961,869 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。挪威银行在第二季度收购了百时美施贵宝的新头寸，价值约为 155.4154 亿美元。查尔斯·施瓦布投资管理公司在第二季度将其在百时美施贵宝的股份增加了 16.8%。查尔斯·施瓦布投资管理公司目前拥有 70,802,680 股该生物制药公司的股票，价值 32.77456 亿美元，此前在上个季度购买了额外的 10,195,775 股。Arrowstreet Capital Limited Partnership 在第二季度将其在百时美施贵宝的持股增加了 428.5%。Arrowstreet Capital Limited Partnership 目前拥有 11,311,281 股该生物制药公司的股票，价值 5.23599 亿美元，此前在上个季度购买了额外的 9,171,098 股。Man Group plc 在第二季度将其在百时美施贵宝的股份增加了 280.4%。Man Group plc 目前拥有 7,465,845 股该生物制药公司的股票，价值 3.45594 亿美元，此前在上个季度购买了额外的 5,503,391 股。最后，富兰克林资源公司在第二季度将其在百时美施贵宝的持股增加了 142.8%。富兰克林资源公司目前拥有 8,436,811 股该生物制药公司的股票，价值 3.90541 亿美元，此前在上个季度购买了额外的 4,961,869 股。76.41% 的股票目前由机构投资者和对冲基金持有。</p>
</div><h2>Bristol Myers Squibb Increases Dividend</h2>
<div class="lb-trans"><h2>百时美施贵宝增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb's previous quarterly dividend of $0.62. Bristol Myers Squibb's dividend payout ratio is currently 83.78%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 2 月 2 日（星期一）支付。1 月 2 日（星期五）登记的股东将获得每股 0.63 美元的股息。这相当于每年 2.52 美元的股息，股息收益率为 4.7%。除息日期为 1 月 2 日（星期五）。这比百时美施贵宝之前的季度股息 0.62 美元有所增加。百时美施贵宝的股息支付比率目前为 83.78%。</p>
</div><h2>About Bristol Myers Squibb</h2>
<div class="lb-trans"><h2>关于百时美施贵宝</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百时美施贵宝公司在全球范围内发现、开发、许可、制造、营销、分销和销售生物制药产品。它提供用于血液学、肿瘤学、心血管、免疫学、纤维化和神经科学疾病的产品。公司的产品包括用于降低非瓣膜性房颤患者中风/全身栓塞风险以及治疗深静脉血栓症/肺栓塞的 Eliquis；用于多种抗癌适应症的 Opdivo，包括膀胱癌、血液癌、结直肠癌、头颈癌、肾细胞癌、肝细胞癌、肺癌、黑色素瘤、胸膜间皮瘤、胃癌和食道癌；用于多发性骨髓瘤的 Pomalyst/Imnovid；用于活动性类风湿关节炎和银屑病关节炎的 Orencia；以及用于治疗费城染色体阳性慢性髓性白血病的 Sprycel。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>What Are Treasury Bonds?</li>
<li>Rate Cuts Make These 3 Income ETFs More Attractive Than Ever</li>
<li>There Are Different Types of Stock To Invest In</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Technology Stocks Explained: Here's What to Know About Tech</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过百时美施贵宝</li>
<li>什么是国债？</li>
<li>降息使这三只收益 ETF 比以往更具吸引力</li>
<li>投资股票有不同类型</li>
<li>在上涨 35% 后，分析师关注铜巨头 Freeport 的更多上涨空间</li>
<li>技术股解析：关于科技你需要知道的</li>
<li>为什么 SpaceX 的 IPO 可能成为 GOOGL 股票的重大催化剂</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在百时美施贵宝吗？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑百时美施贵宝之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而百时美施贵宝并不在名单上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然百时美施贵宝目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zacks Research 发布了对百时美施贵宝收益的乐观预期